Results

1–10 of 43 results for age-related macular degeneration (AMD)

Ixoberogene Soroparvovec (Ixo-vec) IVT Gene Therapy for Neovascular AMD: First-Time 26-Week Interim Analysis Results From the Phase 2 LUNA Study
Charles C Wykoff, MD, PhD, FASRS
Annual Meeting Talks
2024
Association Between Age-Related Macular Degeneration and Diabetic Retinopathy in Type 2 Diabetes Mellitus: A Retrospective Study Using the Vestrum Health Database
Daniel A. Adelberg, MD, FASRS
Annual Meeting Talks
2024
Baseline Factors Associated With 1-Year Outcomes in Phase III Comparison of SB11 (Approved Ranibizumab Biosimilar) With Reference Ranibizumab in nAMD
Neil M. Bressler, MD
Annual Meeting Talks
2022
ReCLAIM-2: Phase 2 Trial of Subcutaneous Elamipretide in Patients with Noncentral Geographic Atrophy
Jeffrey S. Heier, MD
Annual Meeting Talks
2022
Retrospective Real-World Analysis of Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Followed for 3 Years
Ehsan Rahimy, MD
Annual Meeting Talks
2022
Characterizing Real-World Functional Outcomes in Patients with Geographic Atrophy: An IRIS Registry Analysis
Durga Borkar, MD
Annual Meeting Talks
2022
Association of Metformin and Other Antidiabetic Medication Use with Risk of Age-Related Macular Degeneration
Dimitra Skondra, MD,PhD
Annual Meeting Talks
2022
Unsupervised Deep Learning for Grading Age-Related Macular Degeneration Using Retinal Fundus Images
Neesurg S Mehta, MD
On Demand Cases, Courses, and Papers
2021
Visual Impact of Central Subfield Thickness (CST) Fluctuation in Patients With nAMD Treated With Anti-VEGFs in VIEW Trials
Dilsher S. Dhoot, MD
On Demand Cases, Courses, and Papers
2021
Short-term Effects of COVID-19-Related Deferral of Intravitreal Injection Visits
William E. Smiddy, MD
Annual Meeting Talks
2021